Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Constellation Brands
STZ
US Stock MarketDetailed Quotes
ESPR Esperion Therapeutics
- 0.9047
- -0.0153-1.66%
Trading Apr 28 12:48 ET
179.27MMarket Cap-3.23P/E (TTM)
0.9626High0.8890Low1.65MVolume0.9400Open0.9200Pre Close1.51MTurnover0.84%Turnover RatioLossP/E (Static)198.15MShares3.940052wk High-0.46P/B177.29MFloat Cap0.819152wk Low--Dividend TTM195.96MShs Float120.9600Historical High--Div YieldTTM8.00%Amplitude0.7000Historical Low0.9180Avg Price1Lot Size
About Esperion Therapeutics Company
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Company Profile
SymbolESPR
Company NameEsperion Therapeutics
Listing DateJun 26, 2013
Issue Price14.00
Founded1998
CEOMr. Sheldon L. Koenig
MarketNASDAQ
Employees304
Fiscal Year Ends12-31
Address3891 Ranchero Drive,Suite 150
CityAnn Arbor
ProvinceMichigan
CountryUnited States of America
Zip Code48108
Phone1-734-887-3903
Websitehttp://www.esperion.com
Company Executives
- Name
- Position
- Salary
- Sheldon L. Koenig
- Director, President and Chief Executive Officer
- 3.18M
- Benjamin Halladay
- Chief Financial Officer and Principal Accounting Officer
- 1.37M
- J. Martin Carroll
- Chairman of the Board
- 194.83K
- Nicole Vitullo
- Independent Director
- 173.66K
- Robert E. Hoffman, C.P.A.
- Independent Director
- --
- Dr. Antonio M. Gotto,Jr,M.D.,D.Phil.
- Independent Director
- 159.83K
- Tracy M. Woody
- Independent Director
- 176.16K
- Stephen C. Rocamboli
- Independent Director
- 172.33K
- Seth H.Z. Fischer
- Independent Director
- 177.33K
- Jay P. Shepard
- Independent Director
- 174.83K
- Alan Fuhrman
- Independent Director
- 182.33K
- Benjamin O. Looker
- General Counsel
- 1.13M
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now